NovoCure (NVCR) Cash & Equivalents (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.44% |
| Dec 31, 2025 | -72.66% |
| Sep 30, 2025 | 128.65% |
| Jun 30, 2025 | 17.56% |
| Mar 31, 2025 | -22.28% |
| Dec 31, 2024 | -11.68% |
| Sep 30, 2024 | 12.52% |
| Jun 30, 2024 | -63.68% |
| Mar 31, 2024 | 88.42% |
| Dec 31, 2023 | 55.51% |
| Sep 30, 2023 | -1.35% |
| Jun 30, 2023 | -15.59% |
| Mar 31, 2023 | 61.25% |
| Dec 31, 2022 | -52.70% |
| Sep 30, 2022 | -33.57% |
| Jun 30, 2022 | 92.42% |
| Mar 31, 2022 | -8.65% |
| Dec 31, 2021 | -69.73% |
| Sep 30, 2021 | 97.59% |
| Jun 30, 2021 | 10.99% |
| Mar 31, 2021 | 34.04% |
| Dec 31, 2020 | 0.09% |
| Sep 30, 2020 | 19.15% |
| Jun 30, 2020 | 8.17% |
| Mar 31, 2020 | 2.59% |
| Dec 31, 2019 | -14.76% |
| Sep 30, 2019 | 15.53% |
| Jun 30, 2019 | 18.42% |
| Mar 31, 2019 | 8.14% |
| Dec 31, 2018 | 14.36% |
| Sep 30, 2018 | 7.43% |
| Jun 30, 2018 | 2.56% |
| Mar 31, 2018 | 42.00% |
| Dec 31, 2017 | -4.28% |
| Sep 30, 2017 | 2.39% |
| Jun 30, 2017 | -5.20% |
| Mar 31, 2017 | -15.23% |
| Dec 31, 2016 | -13.85% |
| Sep 30, 2016 | 43.22% |
| Jun 30, 2016 | -30.24% |
| Mar 31, 2016 | -2.92% |
| Dec 31, 2015 | 8.25% |
| Sep 30, 2015 | 3.58% |
| Jun 30, 2015 | 43.51% |
| Mar 31, 2015 | 28.82% |
| Dec 31, 2014 | -27.96% |